)
Edge28 Nov 2025
Keeping the Streak Alive: The Story of Duolingo
How Duolingo made language learning addictive, scaled to millions of users, and built a powerful subscription business around everyday practice.
Neurocrine Biosciences (NBIX) investor relations material
Neurocrine Biosciences Jefferies London Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Jefferies London Healthcare Conference 2025 summary18 Nov, 2025
Growth and revenue performance
Achieved $790 million in Q3 revenue, nearly 30% year-over-year growth, with double-digit quarter-to-quarter increases.
Ingrezza generated $687 million in Q3, up 12% year-over-year and 10% quarter-to-quarter, with record new patient starts.
Crinecerfont, launched in December 2024, saw $98 million in Q3 revenue and high reimbursement rates, projecting $400 million annualized.
Revenue diversification is increasing, positioning for strong momentum into 2026.
Full-year guidance for Ingrezza reaffirmed at $2.5–$2.55 billion.
Product strategy and market access
Ingrezza maintains strong market share with less than 10% of 800,000 US patients on VMAT2 inhibitors, indicating significant growth potential.
Expanded Medicare formulary coverage from under 50% to over 70% in 2025, trading some price for volume.
Price per script declined about 7% in the second half of 2024, expected to remain stable through 2026.
Anticipates incremental rebating in 2027–2028 due to IRA and competitive dynamics, but expects to maintain adequate coverage.
Investments in salesforce and market access are driving record new patient starts and organic growth.
Pipeline and R&D productivity
R&D aims to deliver one new medicine every other year by the end of the decade, leveraging expanded expertise in peptides and biologics.
At least four new phase one starts, two phase two starts, and three phase three programs are planned this year.
Focus on neuroscience, including Ozevampitor in phase three for MDD and muscarinic programs for schizophrenia and bipolar mania.
Early-stage programs and VMAT2 follow-on to Ingrezza will be highlighted at the upcoming R&D day.
Collaboration in NLRP3 space aims for an early clinical candidate by 2027.
INGREZZA pricing strategy for 2027-2028
CRENESITY patient identification strategy
Osavampator's differentiation in MDD market
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Neurocrine Biosciences earnings date
Piper Sandler 37th Annual Healthcare Conference2 Dec, 2025
Next Neurocrine Biosciences earnings date
Piper Sandler 37th Annual Healthcare Conference2 Dec, 2025
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Neurocrine Biosciences, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies for neurological, endocrine, and psychiatric disorders. The company focuses on treatments for conditions such as movement disorders, adrenal diseases, and mental health challenges. Neurocrine Biosciences, Inc. is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage